Loading...
Loading...
SCLX| Name | Value |
|---|---|
| Revenues | 9.9M |
| Cost of Revenue | 3.3M |
| Gross Profit | 6.6M |
| Operating Expense | 27.1M |
| Operating I/L | -20.5M |
| Other Income/Expense | -23.5M |
| Interest Income | 0.0M |
| Pretax | -44.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -86.1M |
Scilex Holding Company, a subsidiary of Sorrento Therapeutics, Inc., specializes in developing and commercializing non-opioid management products for acute and chronic pain. Its flagship product, ZTlido 1.8%, is a prescription lidocaine topical product designed to alleviate neuropathic pain associated with post-herpetic neuralgia. Additionally, the company offers SP-102, a gel formulation of corticosteroid for epidural injections in Phase III clinical trials for lumbosacral radicular pain, and SP-103, in Phase II clinical trials for low back pain treatment. Furthermore, Scilex Holding Company has developed SP-104, a low-dose delayed-release naltrexone hydrochloride formulation, which has completed Phase I clinical trials for fibromyalgia treatment.
